Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947733046> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2947733046 abstract "10038 Background: Regorafenib is a multi-kinase inhibitor, developed by adding a fluorine atom to the phenyl ring of sorafenib. Regorafenib inhibits multiple kinases including BRAF, FGFR1, KIT, PDGFRB, RAF, RET, and VEGFR1-3, many at a higher potency than sorafenib. Prior studies within the Pediatric Preclinical Testing Consortium (PPTC) demonstrated sorafenib exhibited intermediate activity for tumor growth inhibition in more than 50% of the sarcoma models tested at a dose of 60mg/kg by oral gavage daily (5 days/wk for 6 consecutive weeks). The in vivo effects of regorafenib were studied in the PPTC osteosarcoma (OS), rhabdomyosarcoma (Rh) and Ewing (EW) sarcoma xenograft models. Methods: The in vivo anticancer effects of regorafenib were assessed in a panel of 6 osteosarcoma models (OS2, OS9, OS31, OS33, OS36, OS60), two rhabdomyosarcoma models (Rh30, Rh41), and one Ewing sarcoma model (EW5). Regorafenib was administered by oral gavage at a dose of 30 mg/kg/day given daily for 21 consecutive days. Time to event and tumor volume responses were defined and analyzed utilizing standard PPTC statistical methods. Results: Regorafenib induced significant improvements in event-free survival (EFS) compared to control in 100% (9/9) of sarcoma models tested. Most models showed pronounced slowing of tumor growth compared to control during the 21 days of regorafenib treatment, with tumor growth generally approximating control rates soon after completion of regorafenib treatment. Three out of 8 sarcoma models demonstrated EFS T/C values > 2 (1/6 OS, 2/2 Rh, 0/1 EW). Minimum relative tumor volumes ranged from 0.74 to 1.60, with no models meeting criteria for objective response. Conclusions: Regorafenib induced modest inhibition of tumor growth in the PPTC sarcoma models evaluated. The overall pattern of response to the multi-kinase inhibitor regorafenib against the PPTC sarcoma models appears similar to that of the kinase inhibitor sorafenib, with pronounced slowing of tumor growth in some models that is limited to the period of agent administration being the primary treatment effect." @default.
- W2947733046 created "2019-06-07" @default.
- W2947733046 creator A5001852513 @default.
- W2947733046 creator A5009981843 @default.
- W2947733046 creator A5032743242 @default.
- W2947733046 creator A5040137655 @default.
- W2947733046 creator A5043927389 @default.
- W2947733046 creator A5044457816 @default.
- W2947733046 creator A5046943976 @default.
- W2947733046 creator A5063003513 @default.
- W2947733046 creator A5068293265 @default.
- W2947733046 creator A5073277560 @default.
- W2947733046 creator A5078531443 @default.
- W2947733046 creator A5090752952 @default.
- W2947733046 date "2019-05-20" @default.
- W2947733046 modified "2023-09-23" @default.
- W2947733046 title "Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma in vivo models." @default.
- W2947733046 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.10038" @default.
- W2947733046 hasPublicationYear "2019" @default.
- W2947733046 type Work @default.
- W2947733046 sameAs 2947733046 @default.
- W2947733046 citedByCount "2" @default.
- W2947733046 countsByYear W29477330462020 @default.
- W2947733046 crossrefType "journal-article" @default.
- W2947733046 hasAuthorship W2947733046A5001852513 @default.
- W2947733046 hasAuthorship W2947733046A5009981843 @default.
- W2947733046 hasAuthorship W2947733046A5032743242 @default.
- W2947733046 hasAuthorship W2947733046A5040137655 @default.
- W2947733046 hasAuthorship W2947733046A5043927389 @default.
- W2947733046 hasAuthorship W2947733046A5044457816 @default.
- W2947733046 hasAuthorship W2947733046A5046943976 @default.
- W2947733046 hasAuthorship W2947733046A5063003513 @default.
- W2947733046 hasAuthorship W2947733046A5068293265 @default.
- W2947733046 hasAuthorship W2947733046A5073277560 @default.
- W2947733046 hasAuthorship W2947733046A5078531443 @default.
- W2947733046 hasAuthorship W2947733046A5090752952 @default.
- W2947733046 hasConcept C121608353 @default.
- W2947733046 hasConcept C126322002 @default.
- W2947733046 hasConcept C142724271 @default.
- W2947733046 hasConcept C143998085 @default.
- W2947733046 hasConcept C150903083 @default.
- W2947733046 hasConcept C19527891 @default.
- W2947733046 hasConcept C207001950 @default.
- W2947733046 hasConcept C2776248978 @default.
- W2947733046 hasConcept C2777586341 @default.
- W2947733046 hasConcept C2777760704 @default.
- W2947733046 hasConcept C2778256501 @default.
- W2947733046 hasConcept C2780844630 @default.
- W2947733046 hasConcept C2994543053 @default.
- W2947733046 hasConcept C502942594 @default.
- W2947733046 hasConcept C526805850 @default.
- W2947733046 hasConcept C71924100 @default.
- W2947733046 hasConcept C86803240 @default.
- W2947733046 hasConceptScore W2947733046C121608353 @default.
- W2947733046 hasConceptScore W2947733046C126322002 @default.
- W2947733046 hasConceptScore W2947733046C142724271 @default.
- W2947733046 hasConceptScore W2947733046C143998085 @default.
- W2947733046 hasConceptScore W2947733046C150903083 @default.
- W2947733046 hasConceptScore W2947733046C19527891 @default.
- W2947733046 hasConceptScore W2947733046C207001950 @default.
- W2947733046 hasConceptScore W2947733046C2776248978 @default.
- W2947733046 hasConceptScore W2947733046C2777586341 @default.
- W2947733046 hasConceptScore W2947733046C2777760704 @default.
- W2947733046 hasConceptScore W2947733046C2778256501 @default.
- W2947733046 hasConceptScore W2947733046C2780844630 @default.
- W2947733046 hasConceptScore W2947733046C2994543053 @default.
- W2947733046 hasConceptScore W2947733046C502942594 @default.
- W2947733046 hasConceptScore W2947733046C526805850 @default.
- W2947733046 hasConceptScore W2947733046C71924100 @default.
- W2947733046 hasConceptScore W2947733046C86803240 @default.
- W2947733046 hasLocation W29477330461 @default.
- W2947733046 hasOpenAccess W2947733046 @default.
- W2947733046 hasPrimaryLocation W29477330461 @default.
- W2947733046 hasRelatedWork W1997533142 @default.
- W2947733046 hasRelatedWork W2046008239 @default.
- W2947733046 hasRelatedWork W2075867443 @default.
- W2947733046 hasRelatedWork W2148968054 @default.
- W2947733046 hasRelatedWork W2152086938 @default.
- W2947733046 hasRelatedWork W2332019204 @default.
- W2947733046 hasRelatedWork W2337112079 @default.
- W2947733046 hasRelatedWork W2408395995 @default.
- W2947733046 hasRelatedWork W2421041953 @default.
- W2947733046 hasRelatedWork W2517521286 @default.
- W2947733046 hasRelatedWork W2521924534 @default.
- W2947733046 hasRelatedWork W2584969752 @default.
- W2947733046 hasRelatedWork W2704905080 @default.
- W2947733046 hasRelatedWork W2891837461 @default.
- W2947733046 hasRelatedWork W2915230518 @default.
- W2947733046 hasRelatedWork W2969866146 @default.
- W2947733046 hasRelatedWork W3012885999 @default.
- W2947733046 hasRelatedWork W3027236081 @default.
- W2947733046 hasRelatedWork W3031573460 @default.
- W2947733046 hasRelatedWork W3047134796 @default.
- W2947733046 isParatext "false" @default.
- W2947733046 isRetracted "false" @default.
- W2947733046 magId "2947733046" @default.
- W2947733046 workType "article" @default.